Canaccord Genuity Reiterates Buy on Intra-Cellular Therapies, Raises Price Target to $65

Canaccord Genuity reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $29 to $65.

Benzinga · 12/24/2019 15:20

Canaccord Genuity reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $29 to $65.